These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 33259598)

  • 1. Long-term remission in multiply relapsed enteropathy-associated T-cell lymphoma following CD30 CAR T-cell therapy.
    Voorhees TJ; Ghosh N; Grover N; Block J; Cheng C; Morrison K; Ivanova A; Dotti G; Serody J; Savoldo B; Beaven AW
    Blood Adv; 2020 Dec; 4(23):5925-5928. PubMed ID: 33259598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30
    Wang D; Zeng C; Xu B; Xu JH; Wang J; Jiang LJ; Wang QX; Li CR; Wang N; Huang L; Zhang YC; Xiao Y; Zhou JF
    Blood Cancer J; 2020 Jan; 10(1):8. PubMed ID: 31974371
    [No Abstract]   [Full Text] [Related]  

  • 3. Challenges of driving CD30-directed CAR-T cells to the clinic.
    Grover NS; Savoldo B
    BMC Cancer; 2019 Mar; 19(1):203. PubMed ID: 30841880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blocking CD30 on T Cells by a Dual Specific CAR for CD30 and Colon Cancer Antigens Improves the CAR T Cell Response against CD30
    Hombach AA; Rappl G; Abken H
    Mol Ther; 2019 Oct; 27(10):1825-1835. PubMed ID: 31331813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric antigen receptor T-cell therapy targeting CD30 in Hodgkin lymphoma.
    Savoldo B
    Clin Adv Hematol Oncol; 2021 Jan; 19(1):24-26. PubMed ID: 33493145
    [No Abstract]   [Full Text] [Related]  

  • 6. A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma.
    Zhao H; Wang Y; Yin ETS; Zhao K; Hu Y; Huang H
    Front Med; 2020 Dec; 14(6):711-725. PubMed ID: 33259039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD30-Redirected Chimeric Antigen Receptor T Cells Target CD30
    Hong LK; Chen Y; Smith CC; Montgomery SA; Vincent BG; Dotti G; Savoldo B
    Cancer Immunol Res; 2018 Oct; 6(10):1274-1287. PubMed ID: 30087115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD30 expression is frequently decreased in relapsed classic Hodgkin lymphoma after anti-CD30 CAR T-cell therapy.
    Marques-Piubelli ML; Kim DH; Medeiros LJ; Lu W; Khan K; Gomez-Bolanos LI; Rodriguez S; Parra ER; Ok CY; Aradhya A; Solis LM; Nieto YL; Steiner R; Ahmed S; Vega F
    Histopathology; 2023 Jul; 83(1):143-148. PubMed ID: 36994939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new immunotherapy strategy targeted CD30 in peripheral T-cell lymphomas: CAR-modified T-cell therapy based on CD30 mAb.
    Wu Y; Chen D; Lu Y; Dong SC; Ma R; Tang WY; Wu JQ; Feng JF; Wu JZ
    Cancer Gene Ther; 2022 Feb; 29(2):167-177. PubMed ID: 33514882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T-cells.
    Guercio M; Orlando D; Di Cecca S; Sinibaldi M; Boffa I; Caruso S; Abbaszadeh Z; Camera A; Cembrola B; Bovetti K; Manni S; Caruana I; Ciccone R; Del Bufalo F; Merli P; Vinti L; Girardi K; Ruggeri A; De Stefanis C; Pezzullo M; Giorda E; Scarsella M; De Vito R; Barresi S; Ciolfi A; Tartaglia M; Moretta L; Locatelli F; Quintarelli C; De Angelis B
    Haematologica; 2021 Apr; 106(4):987-999. PubMed ID: 32381575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of anti-CD30 CAR T cells in Hodgkin lymphoma.
    Veyri M
    Lancet Haematol; 2024 May; 11(5):e314-e316. PubMed ID: 38555922
    [No Abstract]   [Full Text] [Related]  

  • 12. Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantle cell lymphoma.
    Li P; Dong N; Zeng Y; Liu J; Tang X; Wang J; Zhang W; Ye S; Zhou L; Chang AH; Liang A
    Front Med; 2020 Dec; 14(6):811-815. PubMed ID: 32651937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
    Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
    Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case Report: Combined Intravenous Infusion and Local Injection of CAR-T Cells Induced Remission in a Relapsed Diffuse Large B-Cell Lymphoma Patient.
    Hu L; Wu F; Wang H; Zhu W; Wang J; Yu F; Zhai Z
    Front Immunol; 2021; 12():665230. PubMed ID: 33953727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
    Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
    Front Immunol; 2020; 11():564099. PubMed ID: 33329526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relapsed classic Hodgkin lymphoma with decreased CD30 expression after brentuximab and anti-CD30 CAR-T therapies.
    Kim DH; Vega F
    Blood; 2022 Feb; 139(6):951. PubMed ID: 35142847
    [No Abstract]   [Full Text] [Related]  

  • 17. Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
    Cappell KM; Sherry RM; Yang JC; Goff SL; Vanasse DA; McIntyre L; Rosenberg SA; Kochenderfer JN
    J Clin Oncol; 2020 Nov; 38(32):3805-3815. PubMed ID: 33021872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.
    Gu R; Liu F; Zou D; Xu Y; Lu Y; Liu B; Liu W; Chen X; Liu K; Guo Y; Gong X; Lv R; Chen X; Zhou C; Zhong M; Wang H; Wei H; Mi Y; Qiu L; Lv L; Wang M; Wang Y; Zhu X; Wang J
    J Hematol Oncol; 2020 Sep; 13(1):122. PubMed ID: 32894185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric antigen receptor T-cell lymphoma immunotherapy: the next questions.
    Salaroli A; Spilleboudt C; Bron D; Lewalle P
    Curr Opin Oncol; 2020 Sep; 32(5):434-441. PubMed ID: 32796231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial.
    Wang CM; Wu ZQ; Wang Y; Guo YL; Dai HR; Wang XH; Li X; Zhang YJ; Zhang WY; Chen MX; Zhang Y; Feng KC; Liu Y; Li SX; Yang QM; Han WD
    Clin Cancer Res; 2017 Mar; 23(5):1156-1166. PubMed ID: 27582488
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.